This excerpt taken from the TPTX 8-K filed Jun 8, 2006.
Dr. Steven Wagner, Chief Scientific Officer
Dr. Wagner co-founded TorreyPines Therapeutics, then named Neurogenetics, in 2000 as its Chief Scientific Officer. Prior, Dr. Wagner was the Director of Protein Biochemistry at SIBIA Neurosciences. He served as the program head of SIBIAs Alzheimers disease drug discovery collaboration with Bristol-Myers Squibb (BMS). This collaboration resulted in the first gamma-secretase inhibitor for Alzheimers disease to reach the clinic. Dr. Wagner was a member of SIBIAs Strategic Planning and Drug Discovery Steering Committees and a member of the Joint Steering Committee between SIBIA and BMS. Dr. Wagner is an inventor on numerous patents and patent applications and has published over 50 chapters and research papers in the top scientific journals. Prior to leading SIBIAs Alzheimers disease drug discovery efforts, Dr. Wagner was a Research Associate Professor in the Department of Microbiology and Molecular Genetics at the University of California at Irvine where he co-authored the initial purification and identification of the human amyloid precursor protein.